[go: up one dir, main page]

MX2022004215A - Derivados de 2-azaespiro[3.4]octano como agonistas de m4. - Google Patents

Derivados de 2-azaespiro[3.4]octano como agonistas de m4.

Info

Publication number
MX2022004215A
MX2022004215A MX2022004215A MX2022004215A MX2022004215A MX 2022004215 A MX2022004215 A MX 2022004215A MX 2022004215 A MX2022004215 A MX 2022004215A MX 2022004215 A MX2022004215 A MX 2022004215A MX 2022004215 A MX2022004215 A MX 2022004215A
Authority
MX
Mexico
Prior art keywords
sup
agonists
azaspiro
octane derivatives
formula
Prior art date
Application number
MX2022004215A
Other languages
English (en)
Inventor
Michael David Shultz
Keith Jendza
Edward Charles Hall
James Neef
Fan Yang
Xin Chen
Amy Calhoun
Kevin Matthew Gardinier
Nancy Labbe-Giguere
Daniel Steven Palacios
Ming Qian
Christopher G Thomson
Kate Yaping Wang
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2022004215A publication Critical patent/MX2022004215A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)

Abstract

En el presente documento se proporcionan compuestos de acuerdo con la Fórmula (I) (ver Fórmula) (I) o su sal farmacéuticamente aceptable, en donde R1, R2, R3, R5, y R7 se definen en el presente documento. También se proporcionan en el presente documento composiciones farmacéuticas que comprenden un compuesto de Fórmula (I) así como el uso de dichos compuestos como agonistas del receptor M4.
MX2022004215A 2019-10-09 2020-10-07 Derivados de 2-azaespiro[3.4]octano como agonistas de m4. MX2022004215A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962912986P 2019-10-09 2019-10-09
PCT/IB2020/059431 WO2021070091A1 (en) 2019-10-09 2020-10-07 5-oxa-2-azaspiro[3.4]octane derivatives as m4 agonists

Publications (1)

Publication Number Publication Date
MX2022004215A true MX2022004215A (es) 2022-05-03

Family

ID=72944206

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022004215A MX2022004215A (es) 2019-10-09 2020-10-07 Derivados de 2-azaespiro[3.4]octano como agonistas de m4.

Country Status (22)

Country Link
US (3) US11485742B2 (es)
EP (1) EP4041737A1 (es)
JP (1) JP7349567B2 (es)
KR (1) KR102798432B1 (es)
CN (2) CN114555606B (es)
AR (1) AR120169A1 (es)
AU (1) AU2020364186B2 (es)
CA (1) CA3155589A1 (es)
CL (1) CL2022000892A1 (es)
CO (1) CO2022004391A2 (es)
CR (1) CR20220153A (es)
DO (1) DOP2022000075A (es)
EC (1) ECSP22027784A (es)
IL (1) IL291600A (es)
JO (1) JOP20220084A1 (es)
MX (1) MX2022004215A (es)
PE (1) PE20221454A1 (es)
PH (1) PH12022550860A1 (es)
TW (1) TW202128703A (es)
UY (1) UY38907A (es)
WO (1) WO2021070091A1 (es)
ZA (1) ZA202202913B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY38906A (es) * 2019-10-09 2021-05-31 Novartis Ag Compuestos 2- derivados de azaspiro[3,4]octano como agonistas de m4 y composiciones de los mismos
EP4587432A1 (en) * 2022-09-16 2025-07-23 Cerevel Therapeutics, LLC M4 activators/modulators and uses thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060276520A1 (en) 2002-11-13 2006-12-07 Rigel Pharmaceuticals, Inc. Rhodanine derivatives and pharmaceutical compositions containing them
US7479496B2 (en) 2004-02-19 2009-01-20 Bristol-Myers Squibb Company Substituted spiro azabicyclics as modulators of chemokine receptor activity
WO2006006490A1 (ja) 2004-07-08 2006-01-19 Ono Pharmaceutical Co., Ltd. スピロ化合物
WO2006058294A2 (en) * 2004-11-29 2006-06-01 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
CA2661503A1 (en) 2006-08-25 2008-02-28 Vitae Pharmaceuticals, Inc. Inhibitors of 11.beta. -hydroxysteroid dehydrogenase type 1
US20090291134A1 (en) * 2006-11-21 2009-11-26 Jina Pharmaceuticals, Inc. Endoxifen methods and compositions in the treatment of psychiatric and neurodegenerative diseases
AU2009309988A1 (en) 2008-10-29 2010-05-06 Grunenthal Gmbh Substituted spiroamines
US8673931B2 (en) * 2009-01-26 2014-03-18 Abraham Fisher Bicyclic heterocyclic spiro compounds
AU2011328196A1 (en) 2010-11-08 2013-05-02 Janssen Pharmaceuticals, Inc. Radiolabelled mGluR2 PET ligands
CA2827311A1 (en) 2011-02-18 2012-08-23 Vertex Pharmaceuticals Incorporated Chroman-spirocyclic piperidine amides as modulators of ion channels
CA2842841C (en) 2011-07-27 2016-04-19 Nanjing Allgen Pharma Co. Ltd. Spirocyclic molecules as protein kinase inhibitors
HK1210472A1 (en) 2012-09-07 2016-04-22 Zoetis Services Llc Spirocyclic derivatives as antiparasitic agents
AU2013319989C1 (en) 2012-09-18 2017-08-17 Nxera Pharma Uk Limited Bicyclic aza compounds as muscarinic M1 receptor agonists
SI3406609T1 (sl) * 2014-02-06 2024-10-30 Nxera Pharma Uk Limited Biciklične aza spojine kot agonisti muskarinskega receptorja
KR20170090422A (ko) 2014-10-31 2017-08-07 인디비어 유케이 리미티드 도파민 d3 수용체 길항제 화합물
GB201504675D0 (en) 2015-03-19 2015-05-06 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201513742D0 (en) 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonists
GB201513740D0 (en) * 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonist
GB201513743D0 (en) * 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonists
GB2540998A (en) 2015-08-04 2017-02-08 Phagenesis Ltd Catheter
GB201519352D0 (en) 2015-11-02 2015-12-16 Heptares Therapeutics Ltd Pharmaceutical compounds
PT3468966T (pt) 2016-06-10 2020-11-10 Vitae Pharmaceuticals Llc Inibidores da interação menina-mll
GB201617454D0 (en) 2016-10-14 2016-11-30 Heptares Therapeutics Limited Pharmaceutical compounds
CN108456208B (zh) 2017-02-22 2021-04-16 广州市恒诺康医药科技有限公司 氮杂螺环类化合物及其制备方法和应用
WO2018175746A1 (en) 2017-03-24 2018-09-27 Kura Oncology, Inc. Methods for treating hematological malignancies and ewing's sarcoma
AR115015A1 (es) 2018-03-23 2020-11-18 Pfizer Derivados de azaespiro piperazina
GB201810245D0 (en) * 2018-06-22 2018-08-08 Heptares Therapeutics Ltd Pharmaceutical compounds

Also Published As

Publication number Publication date
US11485742B2 (en) 2022-11-01
US11820778B2 (en) 2023-11-21
JP7349567B2 (ja) 2023-09-22
AU2020364186A1 (en) 2022-04-21
PE20221454A1 (es) 2022-09-21
EP4041737A1 (en) 2022-08-17
US20220411435A1 (en) 2022-12-29
CN114555606A (zh) 2022-05-27
JP2022551853A (ja) 2022-12-14
JOP20220084A1 (ar) 2023-01-30
AU2020364186B2 (en) 2023-11-30
CO2022004391A2 (es) 2022-04-29
CL2022000892A1 (es) 2023-01-20
UY38907A (es) 2021-05-31
CN119390705A (zh) 2025-02-07
ECSP22027784A (es) 2022-05-31
CA3155589A1 (en) 2021-04-15
KR20220079608A (ko) 2022-06-13
KR102798432B1 (ko) 2025-04-22
AR120169A1 (es) 2022-02-02
CR20220153A (es) 2022-05-03
PH12022550860A1 (en) 2023-06-14
US20210130365A1 (en) 2021-05-06
CN114555606B (zh) 2024-10-01
WO2021070091A1 (en) 2021-04-15
IL291600A (en) 2022-05-01
TW202128703A (zh) 2021-08-01
ZA202202913B (en) 2023-06-28
DOP2022000075A (es) 2022-05-31
US20240140959A1 (en) 2024-05-02

Similar Documents

Publication Publication Date Title
CR20220371A (es) Agonistas heterocíclicos de glp-1
MX2022008066A (es) Compuestos triciclicos sustituidos.
MX384752B (es) ANTAGONISTAS SOLUBLES DE RECEPTOR DE C5a (C5aR).
MX2022004451A (es) Heteroaril-bifenil-amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1.
PH12021551256A1 (en) Pantetheine derivatives and uses thereof
EP4252848A3 (en) Oxysterols and methods of use thereof
MX383804B (es) Derivados de piperidina.
EP4541422A3 (en) Quinoline derivatives as alpha4beta7 integrin inhibitors
EP4467549A3 (en) Intermediates of n-(3-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)benzamide derivatives
MX394108B (es) Derivados de indol n-sustituidos.
MX2021012223A (es) Compuestos de hexahidro-1h-pirazino[1,2-a]pirazina para el tratamiento de una enfermedad autoinmunitaria.
PH12021552513A1 (en) Pyrrole compounds
MX2021003232A (es) Inhibidores de o-glicoproteina-2-acetamido-2-desoxi-3-d-glucopiran osidasa.
PH12020552186A1 (en) Cyanotriazole compounds and uses thereof
EP4599892A3 (en) Boronic acid derivatives and therapeutic uses thereof
PH12021552953A1 (en) Tricyclic compounds
MX2023009954A (es) Compuestos de aminopirimidina y métodos de uso de estos.
MX2022004215A (es) Derivados de 2-azaespiro[3.4]octano como agonistas de m4.
MX2022004213A (es) Derivados de 2-azaspiro[3.4]octano como agonistas de m4.
MX2021015727A (es) Derivados de piridin-3-ilo.
CR20230218A (es) Nuevos derivados de indazol acetileno
MX2023011027A (es) Derivados de pirimidina utiles como inhibidores de la proteina cinasa de repeticion 2 rica en leucina (lrrk2).
NZ796802A (en) Novel compounds having inhibitory activity on prostaglandin e2 receptor and uses thereof
EA200970570A1 (ru) Макролидные соединения, обладающие противовоспалительной активностью
MX2020008230A (es) Derivados de ester butanoico sustituido con bisfenilo como inhibidores de nep.